These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22275465)

  • 1. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
    Gill KL; Houston JB; Galetin A
    Drug Metab Dispos; 2012 Apr; 40(4):825-35. PubMed ID: 22275465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.
    Cubitt HE; Houston JB; Galetin A
    Pharm Res; 2009 May; 26(5):1073-83. PubMed ID: 19184618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
    Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
    Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
    Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
    Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance.
    Soars MG; Burchell B; Riley RJ
    J Pharmacol Exp Ther; 2002 Apr; 301(1):382-90. PubMed ID: 11907196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.
    Naritomi Y; Nakamori F; Furukawa T; Tabata K
    Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
    Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
    Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data.
    Furukawa T; Nakamori F; Tetsuka K; Naritomi Y; Moriguchi H; Yamano K; Terashita S; Teramura T
    Drug Metab Pharmacokinet; 2012; 27(2):171-80. PubMed ID: 21970858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.
    Rowland A; Knights KM; Mackenzie PI; Miners JO
    Drug Metab Dispos; 2008 Jun; 36(6):1056-62. PubMed ID: 18362158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.
    Gaganis P; Miners JO; Knights KM
    Biochem Pharmacol; 2007 May; 73(10):1683-91. PubMed ID: 17343829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry.
    Badée J; Qiu N; Parrott N; Collier AC; Schmidt S; Fowler S
    Drug Metab Dispos; 2019 Feb; 47(2):124-134. PubMed ID: 30478159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance.
    Knights KM; Spencer SM; Fallon JK; Chau N; Smith PC; Miners JO
    Br J Clin Pharmacol; 2016 Jun; 81(6):1153-64. PubMed ID: 26808419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.
    Knights KM; Winner LK; Elliot DJ; Bowalgaha K; Miners JO
    Br J Clin Pharmacol; 2009 Sep; 68(3):402-12. PubMed ID: 19740398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9.
    Kishi N; Takasuka A; Kokawa Y; Isobe T; Taguchi M; Shigeyama M; Murata M; Suno M; Hanioka N
    Xenobiotica; 2016; 46(4):289-95. PubMed ID: 26247833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro glucuronidation of propofol in microsomal fractions from human liver, intestine and kidney: tissue distribution and physiological role of UGT1A9.
    Mukai M; Tanaka S; Yamamoto K; Murata M; Okada K; Isobe T; Shigeyama M; Hichiya H; Hanioka N
    Pharmazie; 2014 Nov; 69(11):829-32. PubMed ID: 25985579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9.
    Manevski N; Moreolo PS; Yli-Kauhaluoma J; Finel M
    Drug Metab Dispos; 2011 Nov; 39(11):2117-29. PubMed ID: 21856742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine.
    Docci L; Umehara K; Krähenbühl S; Fowler S; Parrott N
    AAPS J; 2020 Oct; 22(6):128. PubMed ID: 33033903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine.
    Shiraga T; Yajima K; Suzuki K; Suzuki K; Hashimoto T; Iwatsubo T; Miyashita A; Usui T
    Drug Metab Dispos; 2012 Feb; 40(2):276-82. PubMed ID: 22031623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1
    Lapham K; Lin J; Novak J; Orozco C; Niosi M; Di L; Goosen TC; Ryu S; Riccardi K; Eng H; Cameron KO; Kalgutkar AS
    Drug Metab Dispos; 2018 Dec; 46(12):1836-1846. PubMed ID: 30194276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
    Cubitt HE; Houston JB; Galetin A
    Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.